Low-dose combinations of LBH589 and TRAIL can overcome TRAIL-resistance in colon cancer cell lines
- Abstract
- BACKGROUND: Despite the considerable advances in the treatment of colorectal cancer, substantial changes in treatment strategies are required to overcome the problems of drug resistance and toxicity. MATERIALS AND METHODS: Combinations of Pan-deacetylase inhibitor LBH589 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were studied in three colon cancer cell lines, HCT116, colo205, and HT29 (HCT116 and colo205 are TRAIL sensitive, whereas HT29 is TRAIL resistant). RESULTS: It was found that TRAIL-induced cytotoxicity was enhanced by LBH589 cotreatment in the TRAIL-sensitive cell lines, and in the TRAIL-resistant HT29 cell line. The cytotoxicity of low-dose TRAIL plus LBH589 was found to be comparable to that of high-dose TRAIL plus LBH589. Additionally, TRAIL and LBH589 were significantly less toxic to normal UCB mononuclear cells than to the three colon cancer cell lines examined. CONCLUSION: LBH589 enhances TRAIL-induced apoptosis in human colon cancer cell lines, especially those resistant to TRAIL-induced apoptosis.
- All Author(s)
- S. C. Lee
; H. J. Cheong
; S. J. Kim
; J. Yoon
; H. J. Kim
; K. H. Kim
; S. H. Kim
; S. B. Bae
; C. K. Kim
; N. Lee
; K. T. Lee
; S. K. Park
; D. S. Hong
; H. S. Park
; J. H. Won
- Issued Date
- 2011
- Type
- Article
- Keyword
- TRAIL; histone deacetylase inhibitor; LBH589; colon cancer; apoptosis
- Publisher
- International Institute of Anticancer Research
- ISSN
- 0250-7005
- Citation Title
- Anticancer Research
- Citation Volume
- 31
- Citation Number
- 10
- Citation Start Page
- 3385
- Citation End Page
- 3394
- Language(ISO)
- eng
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/1456
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.